Objectives: Levosulpiride is a widely used gastroprokinetic agent in the treatment of various gastric disorders; however, its short half-life andincreased dosage frequency leads to non-compliance and possible adverse effects. The prime objective of the current study was to develop asustained-release formulation of Levosulpiride incorporating bioresorbable cellulose derivatives.Materials and Methods: Sustained-release formulations of Levosulpiride were prepared through direct compression using various cellulosederivatives such as CMC sodium, HPC, and HPMC in different polymer-to-drug weight ratios as release-modifying polymers. The powder blendsand compressed tablets were then subjected to pre-compressional and post-compressional evaluation, as well as FTIR analysis. In vitro releasestudies were performed for all formulations of the model drug in buffer solution of pH 6.8 at a wave length of 214 nm by a UV-visible lightspectrophotometer.Results: The FTIR results confirmed that the interaction between components was physical, and from the different kinetic models data, the releaseprofile was best expressed by the Higuchi model because the results showed high linearity. The results also showed formulation F9 to be the idealone among the developed formulations, exhibiting sustained- release behavior.Conclusion: Levosulpiride sustained-release matrices were prepared successfully using CMC sodium, HPC, and HPMC as the release-retardingpolymer/carrier
Amaç: Levosulpirid, çeşitli gastrik bozuklukların tedavisinde yaygın olarak kullanılan bir gastroprokinetik ajandır; bununla birlikte, kısa yarı ömrü ve artan dozlama sıklığı, uyumsuzluk ve olası yan etkilere yol açar. Bu çalışmanın asıl amacı, biyolojik olarak resorbe olabilen selüloz türevlerini içeren Levosulpiridin sürekli salımlı bir formülasyonunu geliştirmektir. Gereç ve Yöntemler: Levosulpiridinin sürekli salım formülasyonları, salım modifiye eden polimerler olarak CMC sodyum, HPC ve HPMC gibi çeşitli selüloz türevlerinin farklı polimer-etkin madde ağırlık oranlarında kullanımıyla direkt basım yoluyla hazırlandı. Daha sonra, toz karışımları ve basılmış tabletler basım öncesi ve basım sonrası değerlendirmeye ve aynı zamanda FTIR analizlerine tabi tutuldu. UV/görünür ışık spektrofotometresi ile 214 nm dalga boyunda pH 6.8 tampon çözeltisinde model etkin maddenin tüm formülasyonları için in vitro salım çalışmaları gerçekleştirildi. Bulgular: FTIR sonuçları, bileşenler arasındaki etkileşimin fiziksel olduğunu ve farklı kinetik model verilerinden, salım profilinin Higuchi modeline en iyi şekilde uyum gösterdiğini doğruladı, çünkü sonuçlar yüksek doğrusallık gösterdi. Sonuçlar ayrıca, geliştirilmiş sürekli salım formülasyonları arasında F9 formülasyonunun ideal olduğunu gösterdi. Sonuç: Salım geciktirici polimer/taşıyıcı olarak CMC sodyum, HPC ve HPMC kullanılarak levosulpirid sürekli salımlı matrisler, başarıyla hazırlandı.
___
Gilhotra RM, Ikram M, Srivastava S, Gilhotra N. A clinical perspective on mucoadhesive buccal drug delivery systems. J Biomed Res. 2014;28:81- 97.
Aulton ME, Taylor K. The Design and Manufacture of Medicines. Aulton’s Pharmaceutics (4th ed). Churchill Livingstone; New York; 2013:894.
Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011;162:1239-1249.
Nokhodchi A, Raja S, Patel P, Asare-Addo K. The role of oral controlled release matrix tablets in drug delivery systems. Bioimpacts. 2012;2:175- 187.
Tanaka N, Imai K, Okimoto K, Ueda S, Tokunaga Y, Ohike A, Ibuki R, Higaki K, Kimura T. Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine. J Control Release. 2005;108:386-395.
Prajapati ST, Patel LD, Patel DM. Gastric floating matrix tablets: design and optimization using combination of polymers. Acta Pharm. 2008;58:221-229.
Sastry SV, Khan MA. Aqueous based polymeric dispersion: Plackett- -Burman design for screening of formulation variables of atenolol gastrointestinal therapeutic system. Pharm Acta Helv. 1998;73:105-112.
Reddy KR, Mutalik S, Reddy S. Once-daily sustained-release matrix tablets of nicorandil: formulation and in vitro evaluation. AAPS PharmSciTech. 2003;4:61.
Florence A, Attwood D. Physicochemical principles of pharmacy: In manufacture, formulation and clinical use (6th ed). Pharmaceutical Press; 2016:296-297.
Salsa T, Veiga F, Pina ME. Oral Controlled-release Dosage Forms. I. Cellulose Ether Polymers in Hydrophilic Matrices. Drug Dev Ind Pharm. 1997;23:929-938.
Guo JH, Skinner GW, Harcum WW, Barnum PE. Pharmaceutical applications of naturally occurring water-soluble polymers. Pharm Sci Technolo Today. 1998;1:254-261.
Liu J, Zhang F, McGinity JW. Properties of lipophilic matrix tablets containing phenylpropanolamine hydrochloride prepared by hot-melt extrusion. Eur J Pharm Biopharm. 2001;52:181-190.
Vueba ML, Batista de Carvalho LA, Veiga F, Sousa JJ, Pina ME. Influence of cellulose ether polymers on ketoprofen release from hydrophilic matrix tablets. Eur J Pharm Biopharm. 2004;58:51-59.
Colombo P. Swelling-controlled release in hydrogel matrices for oral route. Adv Drug Deliv Rev. 1993;11:37-57.
Sinha Roy D, Rohera BD. Comparative evaluation of rate of hydration and matrix erosion of HEC and HPC and study of drug release from their matrices. Eur J Pharm Sci. 2002;16:193-199.
Maev IV, Samsonov AA, Karmanova EA, Ivanchenko EA. The use of prokinetics for the correction of motor and tonic digestive disorders. Klin Med (Mosk). 2009;87:49-53.
Lozano R, Concha MP, Montealegre A, de Leon L, Villalba JO, Esteban HL, Cromeyer M, García JR, Brossa A, Lluberes G, Sandí EI, Quirós HB. Effectiveness and safety of levosulpiride in the treatment of dysmotilitylike functional dyspepsia. Ther Clin Risk Manag. 2007;3:149-155.
Rossi F, Forgione A. Pharmacotoxicological aspects of levosulpiride. Pharmacol Res. 1995;31:81-94.
Distrutti E, Fiorucci S, Hauer SK, Pensi MO, Vanasia M, Morelli A. Effect of acute and chronic levosulpiride administration on gastric tone and perception in functional dyspepsia. Aliment Pharmacol Ther. 2002;16:613-622.
Serra J. Levosulpiride in the management of functional dyspepsia and delayed gastric emptying. Gastroenterol Hepatol. 2010;33:586-590.
Karamanolis G, Tack J. Promotility medications--now and in the future. Dig Dis. 2006;24:297-307.
Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther. 2004;19:379-390.
Herbert MK, Holzer P. Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients--current status and future options. Clin Nutr. 2008;27:25-41.
Nagarsenker MS, Garad SD, Ramprakash G. Design, optimization and evaluation of domperidone coevaporates. J Control Release. 2000;63:31-39.
Xu G, Sunada H. Influence of formulation change on drug release kinetics from hydroxypropylmethylcellulose matrix tablets. Chem Pharm Bull (Tokyo). 1995;43:483-487.
Bourne DWA. Pharmacokinetics. In: Banker GS, Rhodes CT, eds. Modern Pharmaceutics (4th ed). Marcel Dekker Inc; New York; 2002:67.
Higuchi T. Mechanism of sustained action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145-1149.
Hixson AW, Crowell JH. Dependence of Reaction Velocity upon surface and Agitation. Ind Eng Chem. 1931;23:923-931.
Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2001;48:139-157.
Abdel-Rahman SI, Mahrous GM, El-Badry M. Preparation and comparative evaluation of sustained release metoclopramide hydrochloride matrix tablets. Saudi Pharm J. 2009;17:283-288.